Scott Lindquist MD MPH Tuberculosis Medical Consultant Washington State DOH and Kitsap County Health Officer

Similar documents
TB trends and TB genotyping

Tuberculosis Populations at Risk

ANNUAL TUBERCULOSIS REPORT OREGON Oregon Health Authority Public Health Division TB Program November 2012

Global TB Burden, 2016 estimates

I. Demographic Information GENDER NUMBER OF CASES PERCENT OF CASES. Male % Female %

Annual Tuberculosis Report Oregon 2007

Chapter 1 Overview of Tuberculosis Epidemiology in the United States

Tuberculosis Epidemiology

2014 Annual Report Tuberculosis in Fresno County. Department of Public Health

TB EPIDEMIOLOGY. Outline. Estimated Global TB Burden, TB epidemiology

The Epidemiology of Tuberculosis in Minnesota,

Diagnosis and Treatment of Tuberculosis, 2011

Tuberculosis in Chicago 2007

Summary Statistics of Reported and Verified Cases of Tuberculosis in San Joaquin County in 2012, (N=44) County Rate = 6.3 Cases per 100,000 Population

TB in Foreign Born and High Risk Populations

2016 Annual Tuberculosis Report For Fresno County

Tuberculosis in Chicago 2006

Substance Abuse and Tuberculosis Oklahoma City, Oklahoma November 17, 2010

2008 Tuberculosis Report

TB: Management in an era of multiple drug resistance. Bob Belknap M.D. Denver Public Health November 2012

Tuberculosis Tools: A Clinical Update

Yakima Health District BULLETIN

Mycobacterial Infections: What the Primary Provider Should Know about Tuberculosis

The American Experience with TB Elimination

TUBERCULOSIS. Presented By: Public Health Madison & Dane County

Latent Tuberculosis Infections Controversies in Diagnosis and Management Update 2016

Tuberculosis Reporting, Waco-McLennan County Public Health District TB Control WMCPHD (254)

Tuberculosis in Alameda County, 2014 Alameda County Public Health Department

TB in California: Costs, Transmission, and Selecting from the Latent Pool

Core Curriculum on Tuberculosis: What the Clinician Should Know

2015 Annual Report Tuberculosis in Fresno County. Department of Public Health

Fundamentals of Tuberculosis (TB)

Recognizing MDR-TB in Children. Ma. Cecilia G. Ama, MD 23 rd PIDSP Annual Convention February 2016

Tuberculosis: The Big Picture And Challenge of Drug-resistance

Substance Abuse and Tuberculosis Springfield, IL April 27, 2011

Frances Morgan, PhD October 21, Comprehensive Care of Patients with Tuberculosis and Their Contacts October 19 22, 2015 Wichita, KS

TB in Prisons and Jails Albuquerque, New Mexico November 28, 2012

Tuberculosis. WRAIR- GEIS 'Operational Clinical Infectious Disease' Course UNCLASSIFIED

Tuberculosis: A Provider s Guide to

The Elimination of Tuberculosis. Richard E. Chaisson, MD. Center for TB Research Center for AIDS Research Johns Hopkins University

Tuberculosis Infection in the US Military

TB BASICS: PRIORITIES AND CLASSIFICATIONS

Tuberculosis in Alameda County, 2009

Tuberculosis in Alameda County, 2012

Haley Blake Sage Nagai, MPH. Disease Investigation and Intervention Specialists Tuberculosis Treatment and Control Clinic

4/25/2012. The information on patterns of infection and disease can assist in: Assessing current and evolving trends in TB

Research in Tuberculosis: Translation into Practice

Tuberculosis Overview

Treatment of Tuberculosis

The Public Health Impact of TB in the Correctional System. Sarah Bur, RN, MPH Federal Bureau of Prisons Infection Prevention and Control Officer

2014 TUBERCULOSIS FACT SHEET A Profile of Mecklenburg County Reported Cases

Case Management of the TB/HIV Infected Patient

When Can Isolation Be Discontinued?

Failure to Implement the Plan to Eliminate TB in the US: Implications in the Era of Declining Resources

2013 Annual Report Tuberculosis in Fresno County. Department of Public Health

ACTIVE TUBERCULOSIS IN MACOMB COUNTY, A Review of TB Program Data,

TB Laboratory for Nurses

TB Transmission, Pathogenesis & Infection Control

Disclosures. TB and CoMorbidities Challenges and Opportunities. Burden of TB. Outline of the lecture. Target testing for TB Infection TB HIV 3/25/2012

TB BASICS: PRIORITIES AND CLASSIFICATIONS

WASHINGTON STATE COMMUNICABLE DISEASES OF PUBLIC HEALTH SIGNIFICANCE FOR THE CIVIL SURGEON

TB In Detroit 2011* Early TB: Smudge Sign. Who is at risk for exposure to or infection with TB? Who is at risk for TB after exposure or infection?

Targeted Testing and the Diagnosis of. Latent Tuberculosis. Infection and Tuberculosis Disease

The Tip of the Iceberg: Addressing Latent Tuberculosis Infection to Accelerate Tuberculosis Elimination

Global, National, Regional

Tuberculosis in the US Military

Epidemiology of TB: A Local and National Overview

Epidemiology of Tuberculosis in the Northeast Region of the United States Surveillance Data Source. States included in the Northeast Region

Arizona Annual Tuberculosis Surveillance Report

HEALTH SERVICES POLICY & PROCEDURE MANUAL

TB Clinical Guidelines: Revision Highlights March 2014

What you need to know about diagnosing and treating TB: a preventable, fatal disease. Bob Belknap M.D. Denver Public Health November 2013

Tuberculosis Intensive November 17 20, 2015 San Antonio, TX

TB in Corrections Phoenix, Arizona

The authors assessed drug susceptibility patterns

Investigation of Contacts of Persons with Infectious Tuberculosis, 2005

Treatment of Tuberculosis, 2017

Diagnosis and Management of TB Disease Lisa Armitige, MD, PhD September 27, 2011

2017/2018 Annual Volunteer Tuberculosis Notice

Annual Tuberculosis Surveillance Report

TB Grand Rounds. Reynard McDonald, MD & Henry Fraimow, MD January 30, Outline

Global, National, Regional

Asking the Right Questions. A Visual Guide to Tuberculosis Case Management for Nurses. Reference Guide

Global epidemiology of drug-resistant tuberculosis. Factors contributing to the epidemic of MDR/XDR-TB. CHIANG Chen-Yuan MD, MPH, DrPhilos

LATENT TUBERCULOSIS. Robert F. Tyree, MD

Expanding Latent Tuberculosis Infection Testing and Treatment to Accelerate Tuberculosis Elimination

Please distribute a copy of this information to each provider in your organization.

What you need to know about diagnosing and treating TB: a preventable, fatal disease. Bob Belknap M.D. Denver Public Health November 2014

Latent Tuberculosis Infection (LTBI) Questions and Answers for Health Care Providers

HISTORY TB = 25% ADULT DEATHS EGYPTIAN MUMMIES: SPINAL TB. 17 th -18th CENTURIES- URBANIZATION MID 24

Tuberculosis 6/7/2018. Objectives. What is Tuberculosis?

Chapter 4 Diagnosis of Tuberculosis Disease

Tuberculosis in Primary Care COC GTA Spring Symposium Dr Elizabeth Rea April 2013

Latent Tuberculosis Best Practices

HISTORY TB = 25% ADULT DEATHS MID 24 PRE-ANTIBIOTIC ERA

TUBERCULOSIS. Pathogenesis and Transmission

Essential Mycobacteriology Laboratory Services in the Era of MDR- and XDR-TB: A TB Controller s Perspective

HIV as a Risk Factor for TB Henry Pacheco, MD November 13, 2008

Latent Tuberculosis Infection Controversies in Diagnosis and Management of LTBI

Diagnosis and Medical Management of Latent TB Infection

Transcription:

Tuberculosis in the 21 st Century Scott Lindquist MD MPH Tuberculosis Medical Consultant Washington State DOH and Kitsap County Health Officer

Feedback Poll In my opinion, the recent media coverage of the case of drug resistant tuberculosis involving international travel was: A. Balanced B. Overblown C. Confusing D. None of the above

In the World One out of every three persons has been infected with tuberculosis.... Our story begins....

Person

Reported TB Cases by Race/Ethnicity* United States, 2005 Native Hawaiian or Other Pacific Islander (<1%) White (18%) American Indian or Alaska Native (1%) Asian (23%) Hispanic or Latino (29%) Black or African-American (28%) *All races are non-hispanic. Persons reporting two or more races accounted for less than 1% of all cases.

Cases per 100,000 TB Case Rates* by Age Group United States, 1993 2005 20 15 10 5 0 1993 1994 1995 1996 1997 1998 1999 2000 2001 2002 2003 2004 2005 <15 15 24 25 44 45 64 >65 *Updated as of March 29, 2006.

% Coinfection Estimated HIV Coinfection in Persons Reported with TB: United States, 1993 2004* 30 20 10 0 1993 1995 1997 1999 2001 2003 *Updated as of March 29, 2006. All Ages Aged 25 44 Note: Minimum estimates based on reported HIV-positive status among all TB cases in the age group.

% with Test Results Reporting of HIV Test Results in Persons with TB by Age Group: United States, 1993 2004* 80 60 40 20 0 1993 1994 1995 1996 1997 1998 1999 2000 2001 2002 2003 2004 All Ages Aged 25 44 *Updated as of March 29, 2006. Note: Includes TB patients with positive, negative, or indeterminate HIV test results and persons from California reported with AIDS. (HIV test results are not reported from California)

Adult TB Cases by Homeless Status* 1994-2001 % 10 8 6 4 2 0 1994 1995 1996 1997 1998 1999 2000 2001 Adult TB case = TB in person aged >18 years * Homeless within year prior to TB diagnosis

Adult TB Cases by Correctional Facility Status,* 1993-2001 10 8 6 4 2 0 1993 1994 1995 1996 1997 1998 1999 2000 2001 Adult TB case = TB in person aged >18 years old * Resident of correctional facility at the time of TB diagnosis

% of Cases Selected Risk Factors: Ten-Year Period, WA 1993-2005 50 40 30 20 10 0 Unemployed Homeless Alcohol Previous Diagnosis 1994-1995 1996-1997 1998-1999 2000-2001 2002-2003 2004-2005

Place

TB Case Rates*: United States, 2005 D.C. *Cases per 100,000. < 3.5 (year 2000 target) 3.6 4.8 > 4.8 (national average)

Number of Low- Incidence States TB Low-Incidence States,* 1990 2000 25 20 15 10 5 0 1990 1991 1992 1993 1994 1995 1996 1997 1998 1999 2000 * <3.5 TB cases per 100,00 population (Year 2000 target)

Countries of Birth of Foreign-born Persons Reported with TB: US, 2005 Other Countries (38%) Mexico (25%) Philippines (11%) Guatemala (3%) Haiti (3%) China (5%) India (7%) Vietnam (8%)

Trends in TB Cases in Foreign-born Persons: US, 1986 2005* No. of Cases Percentage 10,000 60 8,000 50 40 6,000 30 4,000 20 2,000 10 0 0 86 87 88 89 90 91 92 93 94 95 96 97 98 99 00 01 02 03 04 05 No. of Cases Percentage of Total Cases *Updated as of March 29, 2006.

Proportion of Foreign-born Cases: WA, 1996-2006 90% 75% 60% 59% 61% 63% 60% 70% 72% 69% 66% 68% 67% 73% 45% 30% 15% 0% 1996 1997 1998 1999 2000 2001 2002 2003 2004 2005 2006

Drug Resistance

Drug Resistance Definitions Primary drug resistance Applies to previously untreated patients who are found to have drug- resistant organisms, presumably because they have been infected from an outside source of resistant Mycobacterium tuberculosis. Acquired drug resistance Applies to patients who initially have drugsusceptible bacteria that become drugresistant due to inadequate, inappropriate, or irregular treatment or, more importantly, because of non-adherence in drug taking.

Multidrug-Resistant Tuberculosis (MDR) Resistance to at least two of the best anti- TB drugs, isoniazid and rifampicin. These drugs are considered first line agents.

Extensively Drug Resistant TB (XDR TB) This is a rare type of multidrug-resistant tuberculosis. It is resistant to almost all drugs used to treat TB, including all first line agents and the best second-line agents: fluoroquinolones and at least one of three injectable agents (amikacin, kanamycin, or capreomycin). There have been only 49 cases in the US since 1993.

% Resistant Primary Isoniazid Resistance in U.S.-Born vs. Foreign-Born Persons: US, 1993 2005* 14 12 10 8 6 4 2 0 1993 1995 1997 1999 2001 2003 2005 U.S.-born Foreign-born *Updated as of March 29, 2006. Note: Based on initial isolates from persons with no prior history of TB.

Primary Anti-TB Drug Resistance: WA, 1996-2006 15% INH MDR TB 10% 5% 0% 1996 1997 1998 1999 2000 2001 2002 2003 2004 2005 2006 Note: Based on initial isolates from persons with no prior history of TB. MDR TB defined as resistance to at least isoniazid and rifampin.

Primary MDR TB: US, 1993 2005* No. of Cases Percentage 500 3 400 300 2 200 1 100 0 0 93 94 95 96 97 98 99 00 01 02 03 04 05 No. of Cases Percentage *Updated as of March 29, 2006. Note: Based on initial isolates from persons with no prior history of TB. MDR TB defined as resistance to at least isoniazid and rifampin.

No. of Cases Primary MDR TB: WA,1996-2006 20 15 No. of MDR cases % of Total 50% 40% 10 5 0 1.1% 2.0% 2.0% 2.0% 0.0% 1.0% 0.4% 0.0% 0.4% 1.1% 2.0% 1996 1997 1998 1999 2000 2001 2002 2003 2004 2005 2006 30% 20% 10% 0% Note: Based on initial isolates from persons with no prior history of TB. MDR TB defined as resistance to at least isoniazid and rifampin.

% Primary MDR TB Primary MDR TB in US-born vs. Foreignborn Persons with TB, 1993-2001 3 2 1 0 1993 1994 1995 1996 1997 1998 1999 2000 2001 US-born Foreign-born Note: Based on initial isolates from persons with no prior history of TB. MDR TB defined as resistance to at least isoniazid and rifampin.

New Diagnostics Quantiferon MTD testing Universal genotyping

Commonly Asked TST Questions (1 of 2) How do you know and ensure that the medical community using the TST is properly trained? Can you place a TST on a Thursday and read on a Monday? Who needs a two-step test and why? What is the boosted response?

Commonly Asked TST Questions (2 of 2) What if the longitudinal reading of the TST is 12mm and the horizontal (official reading) is 8mm? Is that considered positive? Can I accept a negative reading if the patient said there was absolutely no reaction and there is no reaction on day four after the test? We switched products from tubersol to aplisol, and I noticed more positives. We retested with tubersol, and all were negative. Which test do I believe?

The Answer Quantiferon Blood-based testing method

MTD Mycobacterium Tuberculosis Direct Test (MTD) Nucleic acid amplification Sensitivity 85.7% 97.8% Criteria for use: Smear-positive cases Highly suspicious cases If it will change treatment

Universal Genotyping All TB cultures from WA state now sent to CDC for genotyping fingerprinting Spoligotyping MIRU pattern Goal is to detect clusters

No. Cases 8 Homeless TB Cases in King County by Treatment Start Date Non-outbreak RFLP No known epi link (RFLP pending) Epi-link (RFLP pending) Outbreak RFLP Second RFLP cluster Clinical case 7 6 5 4 3 2 1 0 Jan Mar May Jul Sep Nov Jan Mar May July Sept Nov Jan Mar May July Sept 2002 Treatment Start Date 2003 2004

Treatment DOT (consistency is key) Latent TB infection nine months Pulmonary six months Meningitis 12 months Adenopathy six months Bone/Joint 12 months Monthly weight check

Treatment Evaluation HIV screen Hep B and C (if risk factors) AST ALT Bilirubin A.Phos. Creatinine Platelets Vision testing (if Ethambutol used > 2 mo.)

Ongoing Diagnostic Monitoring Monthly sputum collection (until two negative smears). Look for smear positive cases after initial two months of therapy. Liver function tests if abnormalities on screening or risk factors for hepatitis.

DOT or Not to DOT Strongly recommended. Patient centered approach is more successful. Social service support Treatment incentives and enablers Housing assistance Substance abuse treatment

TB Case #1: Doc, can he fly home? 17-year-old male exchange student from Azerbaijan. BCG at birth. One month of cough, hemoptysis, weight loss, and acute chest pain. He presents to your office...now what do you do?

Feedback Poll What is your first step? A. Place a PPD and order a chest radiograph B. Place this patient in an N-95 mask C. Start four drug therapy D. All of the above

Results PPD 19 mm Cavitary right upper lobe on radiograph AFB smears all negative

The Rest of the Story Sputum MTD was positive Repeat of the AFB at state lab was positive INH, Rifampin, PZA and Ethambutol started Patient instructed not to fly home Held from last two days of high school Contact investigation begun Host family asks to have him removed from home....

Further Dilemmas Where can he go? When can he fly home? How certain are you that this is not XDR?

Feedback Poll Can he fly home? A. Yes B. No

Contact Dr. Lindquist You can call Dr. Lindquist with your TB-related questions at: 360-337-5237 206-718-2664 Or contact him by e-mail at: lindqs@health.co.kitsap.wa.us